A Model for Individualized Risk Prediction of Contralateral Breast Cancer

对侧乳腺癌个体化风险预测模型

基本信息

  • 批准号:
    8917147
  • 负责人:
  • 金额:
    $ 17.49万
  • 依托单位:
  • 依托单位国家:
    美国
  • 项目类别:
  • 财政年份:
    2014
  • 资助国家:
    美国
  • 起止时间:
    2014-09-01 至 2018-08-31
  • 项目状态:
    已结题

项目摘要

DESCRIPTION (provided by applicant): Patients diagnosed with invasive breast cancer or ductal carcinoma in situ are increasingly choosing to undergo contralateral prophylactic mastectomy (CPM) to reduce their risk of contralateral breast cancer (CBC). This is a particularly disturbing trend as a large number of these CPMs are believed to be medically unnecessary. This is because the risk of CBC has dropped markedly for most patients in the last two decades due to availability of effective adjuvant therapies. Despite this fact, patients diagnosed with first primary breast cancer tend to substantially overestimate their CBC risk. At the same time, they underestimate the complications, risks, and negative effects associated with CPM. These incorrect perceptions partly explain the rising CPM rates in the U.S. Moreover, there is little evidence that CPM helps in prolonging survival. Thus, the benefits of CPM need to be weighed properly with its drawbacks. Given the invasive and irreversible nature of CPM, it behooves us to provide sound and effective education to breast cancer patients, who are going through an emotionally challenging period. Physicians do try to educate their patients; however, they lack tools that can help them in this endeavor. In particular, they need a CBC risk prediction model that can provide individualized risk estimates for sporadic (non-genetic) breast cancer patients. This project aims to fill this need by developing such a model, validating it, and implementing it in a freely available software package for immediate clinical use. To build the model, we will use data from Surveillance, Epidemiology, and End Results (SEER) Program and meta-analysis of risk estimates from literature. The proposed model will be in the style of the Gail model - a popular tool for counseling women on the risk of developing breast cancer - but one that is exclusively designed for counseling women with unilateral breast cancer on the risk of developing CBC. After building the model, we will validate it on prospectively collected data on breast cancer patients from four institutions - University of Texas at Southwestern Medical Center, Parkland Memorial Hospital in Dallas, M D Anderson Cancer Center, and Dartmouth Medical School. Once the model is validated, we will create a user-friendly package in statistical software R for implementing the model. Then we will integrate the package into CancerGene, a widely used and freely available clinical software for counseling patients on the risk of breast cancer. CancerGene is licensed to more than 4000 sites worldwide and therefore will be a perfect gateway to make the new model available to a large number of practitioners. We believe our proposed model will greatly facilitate patients' education and will help stem the increasing trend of medically unnecessary CPMs.
描述(由申请人提供):越来越多被诊断为浸润性乳腺癌或原位导管癌的患者选择行对侧预防性乳房切除术(CPM)以降低患对侧乳腺癌(CBC)的风险。这是一个特别令人不安的趋势,因为许多cpm被认为在医学上是不必要的。这是因为在过去二十年中,由于有效的辅助治疗的可用性,大多数患者的CBC风险显着下降。尽管如此,被诊断为原发性乳腺癌的患者往往大大高估了他们的CBC风险。同时,他们低估了与CPM相关的并发症、风险和负面影响。这些错误的认知部分解释了美国CPM率上升的原因。此外,几乎没有证据表明CPM有助于延长生存期。因此,需要适当地权衡CPM的优点和缺点。鉴于CPM的侵袭性和不可逆性,我们有必要为正在经历情感挑战时期的乳腺癌患者提供健全有效的教育。医生确实试图教育他们的病人;然而,他们缺乏能够帮助他们完成这项工作的工具。特别是,他们需要一个CBC风险预测模型,可以为散发性(非遗传性)乳腺癌患者提供个性化的风险估计。本项目旨在通过开发这样一个模型,验证它,并满足这一需求

项目成果

期刊论文数量(2)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
CBCRisk-Black: a personalized contralateral breast cancer risk prediction model for black women.
  • DOI:
    10.1007/s10549-022-06612-5
  • 发表时间:
    2022-07
  • 期刊:
  • 影响因子:
    3.8
  • 作者:
    Sajal, Ibrahim Hossain;Chowdhury, Marzana;Wang, Tingfang;Euhus, David;Choudhary, Pankaj K.;Biswas, Swati
  • 通讯作者:
    Biswas, Swati
{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ monograph.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ sciAawards.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ conferencePapers.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ patent.updateTime }}

Swati Biswas其他文献

Swati Biswas的其他文献

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

{{ truncateString('Swati Biswas', 18)}}的其他基金

A Model for Individualized Risk Prediction of Contralateral Breast Cancer
对侧乳腺癌个体化风险预测模型
  • 批准号:
    8692361
  • 财政年份:
    2014
  • 资助金额:
    $ 17.49万
  • 项目类别:
Identifying rare haplotype-environment interactions using Logistic Bayesian Lasso
使用逻辑贝叶斯套索识别罕见的单倍型-环境相互作用
  • 批准号:
    8587302
  • 财政年份:
    2012
  • 资助金额:
    $ 17.49万
  • 项目类别:
Identifying rare haplotype-environment interactions using Logistic Bayesian Lasso
使用逻辑贝叶斯套索识别罕见的单倍型-环境相互作用
  • 批准号:
    8508230
  • 财政年份:
    2012
  • 资助金额:
    $ 17.49万
  • 项目类别:

相似海外基金

Countering sympathetic vasoconstriction during skeletal muscle exercise as an adjuvant therapy for DMD
骨骼肌运动期间对抗交感血管收缩作为 DMD 的辅助治疗
  • 批准号:
    10735090
  • 财政年份:
    2023
  • 资助金额:
    $ 17.49万
  • 项目类别:
The ESCAPE clinical trial of circulating tumor DNA to guide adjuvant therapy in chemo-resistant triple negative breast cancer
循环肿瘤 DNA 指导化疗耐药三阴性乳腺癌辅助治疗的 ESCAPE 临床试验
  • 批准号:
    494901
  • 财政年份:
    2023
  • 资助金额:
    $ 17.49万
  • 项目类别:
    Operating Grants
A Type I Hybrid Effectiveness-Implementation Trial to Evaluate a Navigation-Based Multilevel Intervention to Decrease Delays Starting Adjuvant Therapy Among Patients with Head and Neck Cancer
一项 I 型混合有效性实施试验,用于评估基于导航的多级干预措施,以减少头颈癌患者开始辅助治疗的延迟
  • 批准号:
    10714537
  • 财政年份:
    2023
  • 资助金额:
    $ 17.49万
  • 项目类别:
Multi-modal machine learning to guide adjuvant therapy in surgically resectable colorectal cancer
多模式机器学习指导可手术切除结直肠癌的辅助治疗
  • 批准号:
    10588103
  • 财政年份:
    2023
  • 资助金额:
    $ 17.49万
  • 项目类别:
Efficacy of ethanol adjuvant therapy after resection of malignant soft tissue tumors
恶性软组织肿瘤切除术后乙醇辅助治疗的疗效
  • 批准号:
    22K09407
  • 财政年份:
    2022
  • 资助金额:
    $ 17.49万
  • 项目类别:
    Grant-in-Aid for Scientific Research (C)
Identification of immune response cells and development of novel adjuvant therapy for sublingual immunotherapy
免疫应答细胞的鉴定和舌下免疫治疗新型辅助疗法的开发
  • 批准号:
    21KK0287
  • 财政年份:
    2022
  • 资助金额:
    $ 17.49万
  • 项目类别:
    Fund for the Promotion of Joint International Research (Fostering Joint International Research (A))
Pursuing molecular biomarkers to guide adjuvant therapy for HPV+ head and neck cancers after transoral robotic surgery
寻找分子生物标志物来指导经口机器人手术后 HPV 头颈癌的辅助治疗
  • 批准号:
    10357120
  • 财政年份:
    2022
  • 资助金额:
    $ 17.49万
  • 项目类别:
Biomarker research using two prospective studies on preoperative and postoperative adjuvant therapy for pancreatic cancer
使用两项关于胰腺癌术前和术后辅助治疗的前瞻性研究进行生物标志物研究
  • 批准号:
    21K08700
  • 财政年份:
    2021
  • 资助金额:
    $ 17.49万
  • 项目类别:
    Grant-in-Aid for Scientific Research (C)
Personalized Resistant Starch as an Adjuvant Therapy for Pediatric Inflammatory Bowel Disease
个性化抗性淀粉作为小儿炎症性肠病的辅助治疗
  • 批准号:
    437315
  • 财政年份:
    2020
  • 资助金额:
    $ 17.49万
  • 项目类别:
    Studentship Programs
Tailored adjuvant therapy in POLE-mutated and p53-wildtype early stage endometrial cancer (TAPER)
POLE 突变和 p53 野生型早期子宫内膜癌 (TAPER) 的定制辅助治疗
  • 批准号:
    435603
  • 财政年份:
    2020
  • 资助金额:
    $ 17.49万
  • 项目类别:
    Operating Grants
{{ showInfoDetail.title }}

作者:{{ showInfoDetail.author }}

知道了